awmsg logo



insulin glargine (Lantus®)


Reference No. 1673

Publication date:
22/03/2013


Last review date:
30/09/2016

Appraisal information

insulin glargine (Lantus®) 100 units/ml solution for injection


Company: Sanofi-Aventis Ltd
BNF category: Endocrine system
NMG meeting date: 09/01/2013
AWMSG meeting date: 06/02/2013
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 0413
Ministerial ratification: 18/03/2013

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Insulin glargine (Lantus®) 100 units/ml solution for injection is recommended as an option for use within NHS Wales for the treatment of diabetes mellitus in children aged 2 to less than 6 years.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download